Maria Kelman - PIRS Old Executive Relations
Executive
Maria Kelman is Executive Relations of PIRS Old
| Phone | 857 246 8998 |
| Web | https://www.pieris.com |
PIRS Old Management Efficiency
The company has return on total asset (ROA) of (0.1318) % which means that it has lost $0.1318 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8046) %, meaning that it created substantial loss on money invested by shareholders. PIRS Old's management efficiency ratios could be used to measure how well PIRS Old manages its routine affairs as well as how well it operates its assets and liabilities.PIRS Old currently holds 11.92 M in liabilities with Debt to Equity (D/E) ratio of 0.3, which may suggest the company is not taking enough advantage from borrowing. PIRS Old has a current ratio of 2.51, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about PIRS Old's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| James MD | Corvus Pharmaceuticals | N/A | |
| Dr MBA | Agenus Inc | N/A | |
| Scott Harris | Terns Pharmaceuticals | N/A | |
| David Ege | ADC Therapeutics SA | 51 | |
| Lisa Kallebo | ADC Therapeutics SA | N/A | |
| Michael Wolf | Affimed NV | 58 | |
| Lars MBA | PDS Biotechnology Corp | 55 | |
| Gayle Gironda | Inozyme Pharma | N/A | |
| Zack Armen | Agenus Inc | N/A | |
| Peter Esq | ADC Therapeutics SA | 58 | |
| Sanjay Zaveri | PDS Biotechnology Corp | N/A | |
| John Lunger | Adaptimmune Therapeutics Plc | 55 | |
| Shree Patel | Achilles Therapeutics PLC | N/A | |
| JD Esq | Terns Pharmaceuticals | 56 | |
| Spencer JD | PDS Biotechnology Corp | 55 | |
| Marcy Graham | ADC Therapeutics SA | 58 | |
| Robert Arbeit | X4 Pharmaceuticals | 77 | |
| Daniel Hood | Achilles Therapeutics PLC | N/A | |
| Gregory Conn | PDS Biotechnology Corp | 70 | |
| Divya Vasudevan | Agenus Inc | N/A | |
| Dana Lynch | Adaptimmune Therapeutics Plc | N/A | |
Management Performance
| Return On Equity | -0.8 | |||
| Return On Asset | -0.13 |
PIRS Old Leadership Team
Elected by the shareholders, the PIRS Old's board of directors comprises two types of representatives: PIRS Old inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PIRS. The board's role is to monitor PIRS Old's management team and ensure that shareholders' interests are well served. PIRS Old's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PIRS Old's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Maria Kelman, Executive Relations | ||
| Thomas Bures, Senior CFO | ||
| Prompong Chaikul, Chief Officer | ||
| Ahmed JD, Chief VP | ||
| Gordon MD, Head Oncology | ||
| Stephen JD, President CEO | ||
| Florian Witte, VP Leadership | ||
| Christine Rothe, VP Science | ||
| Hitto Kaufmann, VP Officer | ||
| Frank Vollmering, Vice Resources | ||
| Shane Olwill, Senior Officer |
PIRS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PIRS Old a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.8 | |||
| Return On Asset | -0.13 | |||
| Profit Margin | (1.14) % | |||
| Operating Margin | (0.57) % | |||
| Current Valuation | (8.41 M) | |||
| Shares Outstanding | 1.32 M | |||
| Shares Owned By Insiders | 0.06 % | |||
| Shares Owned By Institutions | 52.92 % | |||
| Number Of Shares Shorted | 23.56 K | |||
| Price To Earning | (6.95) X |
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in PIRS Stock
If you are still planning to invest in PIRS Old check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PIRS Old's history and understand the potential risks before investing.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Stocks Directory Find actively traded stocks across global markets |